Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT03219307
Active, not recruiting Phase 3

NOVOCART 3D Treatment Following Microfracture Failure

NCT03219307 · tracked via the Priya Life Science USA tracker
Sponsor
Aesculap Biologics, LLC
Phase
Phase 3
Started
2018-11-30
Last updated
2025-03-21

Condition(s) studied

Articular Cartilage Defect

Investigational drug(s) / intervention(s)

NOVOCART 3D

NOVOCART 3D: Matrix associated autologous chondrocyte implant

Study summary

This study is prospective single arm extension study of protocol AAG-G-H-1220. It is open only to participants of AAG-G-H-1220 randomized to the Microfracture treatment group.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * participated in study AAG-G-H-1220 * identified as a microfracture failure patient * voluntary consent to participate in the study Exclusion Criteria: * other cartilage repair procedures performed on target knee * other conditions that would interfere with healing or evaluating outcomes * lesions requiring implants larger than 9cm2 * non-compliance with requirements in study AAG-G-H-1220

Primary outcome measure(s)

  • KOOS pain subdomain score — 24 months
    Comparison of pain scores from the KOOS questionnaire from baseline

Trial sites (5)

FacilityCityRegionStatus
Rush University Medical Center Chicago Illinois
Ohio State University Wexner Medical Center Columbus Ohio
Alpine Orthopaedics North Logan Utah
University of Alberta Edmonton Alberta
Dalhousie University Halifax Nova Scotia

More Aesculap Biologics, LLC trials in the USA

NOVOCART®3D for Treatment of Articular Cartilage of the Knee Active, not recruiting

Other trials for the same condition

Phase 2 Clinical Trial of CartiLife® in the United States Recruiting
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle Recruiting
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03219307 on ClinicalTrials.gov ↗ ← All trials in the USA